20 categories

Compounds

One subcategory per compound family. Pharmacology, published data, practical experience, and the maintained reference page for each.

207 topics10,207 posts73 solved Moderators: hana.sato, j.mwangi About this category

Semaglutide 35 Tirzepatide 30 Retatrutide 26 Cagrilintide & amylin analogues 24 Oral incretins 24 Secretagogues & GH axis 24 Repair & healing peptides 22 Other compounds 22

207 topics

Topic	Participants	Replies	Views	Activity
Oral semaglutide bioavailability and its variability between people — a second dataset Compounds › Oral incretins randomised trial PIONEER programme SOUL trial Closed Oral semaglutide bioavailability and its variability between people — a second dataset — setting out what I have, and where I think it stops being reliable. Posting a small dataset on Oral semaglutide…	+141	154	47k	19mo
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly Compounds › Tirzepatide tirzepatide SURPASS programme randomised trial effect size Solved Closed Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin tirzepatide in type 2…	+150	163	22k	11mo
Retatrutide dose escalation in the published trials Compounds › Retatrutide preprint retatrutide effect size Posting this under the heading it deserves: Retatrutide dose escalation in the published trials Everything below is what sits behind that. An honest uncertainty about retatrutide dose escalation rather than a…	+149	159	30k	15mo
Amylin analogue mechanism: satiety signalling separate from GLP-1 Compounds › Cagrilintide & amylin analogues effect size randomised trial cagrilintide cagrisema Solved Amylin analogue mechanism: satiety signalling separate from GLP-1 — setting out what I have, and where I think it stops being reliable. Trying to work out what would count as evidence on amylin analogue…	+128	142	38k	13mo
When "no data" is the complete and final answer Compounds › Other compounds custom synthesis mislabelling needs a source research use only Solved Asking directly, because I could not find a straight answer: When "no data" is the complete and final answer Asking about the compound itself rather than about a trial of it. I have read the maintained page…	+154	165	6.3k	15mo
Reading a preclinical wound-healing model and its relevance to a human tendon Compounds › Repair & healing peptides TB-500 preprint observational data Wiki Closed On the subject in the title: Reading a preclinical wound-healing model and its relevance to a human tendon Working notes rather than a conclusion. Posting a small dataset on reading a preclinical…	+149	160	3.3k	20mo
Second pass at: Why this subcategory is stricter about sourcing than most Compounds › Secretagogues & GH axis observational data ipamorelin tesamorelin needs a source Second pass at: Why this subcategory is stricter about sourcing than most — setting out what I have, and where I think it stops being reliable. A comparison question rather than a question about one compound.…	+120	129	61k	11mo
SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on Compounds › Tirzepatide SURMOUNT programme randomised trial tirzepatide SURPASS programme Solved Closed Posting this under the heading it deserves: SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on Everything below is what sits behind that. I would like to disagree carefully…	+122	136	48k	9mo
The CagriSema phase 2 paper and what a fixed combination buys — the long version Compounds › Cagrilintide & amylin analogues amylin analogues cagrisema cagrilintide The CagriSema phase 2 paper and what a fixed combination buys — the long version Writing it up because I had to work it out twice and would rather nobody else did. A narrow question about CagriSema phase 2…	+137	158	17k	13mo
Semaglutide half-life: where the 165 to 184 hour figure comes from — what changed since Compounds › Semaglutide STEP programme type 2 diabetes randomised trial effect size Posting this under the heading it deserves: Semaglutide half-life: where the 165 to 184 hour figure comes from — what changed since Everything below is what sits behind that. Putting the numbers in the first…	+125	132	39k	16mo
Revisiting: Melanocortin agonists: mechanism and the documented adverse profile Compounds › Other compounds custom synthesis mislabelling research use only Solved Posting this under the heading it deserves: Revisiting: Melanocortin agonists: mechanism and the documented adverse profile Everything below is what sits behind that. Melanocortin agonists, from the point of…	+119	141	22k	20mo
[2026 update] What the GIP component of tirzepatide is thought to contribute, and how confident we can be Compounds › Tirzepatide SURPASS programme randomised trial effect size Under review The question in the title: What the GIP component of tirzepatide is thought to contribute, and how confident we can be I will give what I have already checked below so nobody repeats it. I would like to know…	+109	124	31k	10mo
Second pass at: Retatrutide dose escalation in the published trials Compounds › Retatrutide retatrutide randomised trial preprint Under review Second pass at: Retatrutide dose escalation in the published trials — setting out what I have, and where I think it stops being reliable. Two things I would like separated before anyone answers on Retatrutide…	+115	125	30k	2y
Follow-up: Tirzepatide's shorter half-life and its one practical consequence Compounds › Tirzepatide tirzepatide SURPASS programme SURMOUNT programme effect size Solved Tirzepatide's shorter half-life and its one practical consequence Writing it up because I had to work it out twice and would rather nobody else did. Documentation question rather than a pharmacological one,…	+130	137	11k	19mo
The 2.5 mg starting dose is not a therapeutic dose — why that matters Compounds › Tirzepatide SURPASS programme SURMOUNT programme effect size Solved The 2.5 mg starting dose is not a therapeutic dose — why that matters Writing it up because I had to work it out twice and would rather nobody else did. A follow-up question about 2.5 mg starting dose that I…	+119	136	5.6k	2mo
Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one Compounds › Oral incretins oral semaglutide randomised trial PIONEER programme SOUL trial Solved Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one I have a specific reason for asking rather than idle curiosity, and the context is below. A methods question rather than a…	+130	135	11k	7mo
Semaglutide half-life: where the 165 to 184 hour figure comes from Compounds › Semaglutide semaglutide effect size randomised trial type 2 diabetes Wiki Semaglutide half-life: where the 165 to 184 hour figure comes from — setting out what I have, and where I think it stops being reliable. Putting the numbers in the first post, because a question about a…	+128	145	3k	4mo
Reading a supplier's product description as a marketing document Compounds › Other compounds custom synthesis needs a source mislabelling On the subject in the title: Reading a supplier's product description as a marketing document Working notes rather than a conclusion. Documentation question rather than a pharmacological one, but about this…	+86	97	62k	8mo
What SELECT changed about how semaglutide is discussed, and what it did not Compounds › Semaglutide STEP programme type 2 diabetes randomised trial Solved Asking directly, because I could not find a straight answer: What SELECT changed about how semaglutide is discussed, and what it did not I was wrong about SELECT in a thread last spring and I would like to…	+120	132	2k	14mo
TB-500 and thymosin beta-4: the fragment versus the protein Compounds › Repair & healing peptides observational data TB-500 BPC-157 preprint TB-500 and thymosin beta-4: the fragment versus the protein Writing it up because I had to work it out twice and would rather nobody else did. TB-500 and thymosin beta-4: what I expected, what I found, and…	+107	118	22k	11mo
What is genuinely unknown about long-term amylin agonism Compounds › Cagrilintide & amylin analogues randomised trial cagrilintide cagrisema amylin analogues Solved What is genuinely unknown about long-term amylin agonism — that is the question, and I have not found it answered plainly anywhere I have looked. A comparison question rather than a question about one…	+83	91	46k	1d
Follow-up: Tirzepatide and nausea: is the profile genuinely different or just differently reported? Compounds › Tirzepatide tirzepatide SURMOUNT programme effect size randomised trial Solved Tirzepatide and nausea: is the profile genuinely different or just differently reported? I have a specific reason for asking rather than idle curiosity, and the context is below. Something about Tirzepatide…	+109	122	3.6k	2mo
BPC-157: what the rodent literature actually shows, and what it does not — a second dataset Compounds › Repair & healing peptides TB-500 preprint observational data needs a source Solved On the subject in the title: BPC-157: what the rodent literature actually shows, and what it does not — a second dataset Working notes rather than a conclusion. The question about BPC-157 that I actually want…	+77	84	54k	11mo
Why cagrilintide alone is discussed so much less than in combination Compounds › Cagrilintide & amylin analogues effect size amylin analogues cagrisema Solved Closed Why cagrilintide alone is discussed so much less than in combination I have a specific reason for asking rather than idle curiosity, and the context is below. Collecting what is known about cagrilintide alone…	+93	108	35k	16mo
Cagrilintide's dosing interval and the pharmacokinetics behind it Compounds › Cagrilintide & amylin analogues effect size randomised trial amylin analogues cagrisema Solved Cagrilintide's dosing interval and the pharmacokinetics behind it — setting out what I have, and where I think it stops being reliable. Putting the numbers in the first post, because a question about a…	+98	105	24k	10mo
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile Compounds › Semaglutide STEP programme type 2 diabetes randomised trial SELECT trial Posting this under the heading it deserves: Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile Everything below is what sits behind that. Semaglutide and gastric emptying,…	+115	122	2.6k	1d
What the published dose-response for semaglutide actually looks like above 2.4 mg — a second dataset Compounds › Semaglutide STEP programme randomised trial SELECT trial type 2 diabetes Solved Asking directly, because I could not find a straight answer: What the published dose-response for semaglutide actually looks like above 2.4 mg — a second dataset Two things I would like separated before…	+112	130	2.2k	16mo
Coming back to: Semaglutide half-life: where the 165 to 184 hour figure comes from Compounds › Semaglutide SELECT trial type 2 diabetes semaglutide Semaglutide half-life: where the 165 to 184 hour figure comes from Writing it up because I had to work it out twice and would rather nobody else did. Putting the numbers in the first post, because a question…	+112	119	3.3k	11mo
Compounds this community declines to help with, and why Compounds › Other compounds research use only needs a source mislabelling custom synthesis Solved Wiki Compounds this community declines to help with, and why — setting out what I have, and where I think it stops being reliable. Putting the numbers in the first post, because a question about a compound without…	+81	87	35k	10mo
Research-use-only status: what it means legally and practically — a second dataset Compounds › Other compounds research use only mislabelling needs a source custom synthesis Solved Research-use-only status: what it means legally and practically — a second dataset — setting out what I have, and where I think it stops being reliable. Posting a small dataset on Research-use-only status. It…	+109	125	2k	16mo

Sponsored Sigma-Aldrich — certified reference materialsReference standards, analytical reagents and certified materials for method calibration. If you are validating a method, this is where the standard comes from.Reference standards →